黒色腫の免疫療法への耐性進化のメカニズムを解明(Scientists now know how melanoma evolves to resist immunotherapy)

ad

2025-11-04 カリフォルニア大学ロサンゼルス校(UCLA)

Web要約 の発言:
UCLA健康総合がんセンターの研究により、悪性黒色腫(メラノーマ)が免疫療法に抵抗する進化メカニズムが解明された。腫瘍はDNAコピー数の増減(増幅・欠失)によって細胞死関連遺伝子を改変し、免疫攻撃による自己崩壊を回避することが判明。これにより、治療で一時的に縮小した腫瘍が数か月〜数年後に再発する。研究チームは、腫瘍細胞を再び自己崩壊しやすくする戦略が免疫チェックポイント阻害剤の効果維持に有効と示唆。成果はImmunity誌に掲載され、がん治療抵抗性克服の新たな分子標的の可能性を示した。

<関連情報>

ゲノムコピー数変異は免疫チェックポイント阻害剤に対する獲得耐性の根底にあるアポトーシス回避を促進する Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors

Mingming Wu ∙ Shiyue Yang ∙ Zhentao Yang ∙ … ∙ Douglas B. Johnson ∙ Sixue Liu ∙ Roger S. Lo
Immunity  Published:October 31, 2025
DOI:https://doi.org/10.1016/j.immuni.2025.10.001

Graphical abstract

黒色腫の免疫療法への耐性進化のメカニズムを解明(Scientists now know how melanoma evolves to resist immunotherapy)

Highlights

  • Acquired-resistant melanomas amplify anti-apoptotic and/or delete pro-apoptotic genes
  • Models of acquired ICI resistance recapitulate apoptotic evasion due to CNVs
  • Preexisting and de novo resistance-driver CNVs occur commonly or privately in subclones
  • Lowering the apoptotic threshold salvages ICI sensitivity and prevents relapse

Summary

Patients who initially respond to immune checkpoint inhibitors (ICIs) often relapse. Here, we studied how disease-progressive (DP) clinical melanomas evolve genomically to acquire ICI resistance. Compared to patient-matched pretreatment tumors, DP tumors recurrently amplified and/or deleted anti-apoptotic and/or pro-apoptotic genes, respectively. By chronic exposure to killer T cells or ICI therapy, we derived acquired-resistant (AR) human melanoma cell lines and murine melanoma tumors that recapitulate co-occurrent copy-number variants (CNVs) of apoptotic genes observed in DP melanomas. AR and DP subclones expanded shared, private, and, in some subclones, preexistent driver CNVs. Compared to isogenic parental cells, AR melanoma cells attenuated apoptotic priming but, with overexpression of deleted pro-apoptotic genes, recovered mitochondrial priming and sensitivity to killer T cells or ICIs. In mice, pharmacologically reducing the apoptotic threshold of ICI persisters prevented relapses. Thus, CNVs can drive the evolution of resistance to ICIs in melanoma, with tumor cell-intrinsic apoptotic threshold representing a target to curtail persister evolution.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました